Clinical trials: Gastrointestinal Carcinoid Tumor
Neuroendocrine Tumor
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects.
- Trial name
- NCT00789841
- Testing
- Magnetic Tracking System (MTS) and radio-opaque markers
- Where
- Denmark
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroendocrine Tumors, Carcinoid Tumor
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- NCT04915144
- Testing
- 177Lu-DOTATOC
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse.
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor
- Trial name
- NCT01841736
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 423 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor…
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00002475
- Testing
- allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Vincent Medical Center - Los Angeles
Midgut Carcinoid Tumor, Biliary Stones
Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.
The investigators want to study the effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery.
- Trial name
- TNE-IDC-COLE (NCT04735198)
- Testing
- Primary tumor surgery, Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy
- Where
- 6 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitari de Bellvitge
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Neuroendocrine Tumor, Carcinoid Tumor
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
The purpose of this research study is to determine the effectiveness of AMG 479 against carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the laboratory.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT01024387
- Testing
- AMG 479
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates.
- Conditions
- Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net
- Trial name
- RGS-GEP-NET (NCT05448157)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
RATIONALE: The use of endoscopy to place a metal stent in the large intestine is less invasive than surgery for treating cancer-related bowel obstruction and may have fewer side effects and improve recovery.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00004911
- Testing
- bowel obstruction management, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1…
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06016855
- Testing
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Islet Cell Tumor
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Trial name
- NCT00466856
- Testing
- octreotide acetate, yttrium Y 90 resin microspheres
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Carcinoid Tumors, Pancreatic NET
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
This is a prospective phase II open-label trial, stratifying patients equally into two cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs).
- Trial name
- NCT02575300
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Carcinoid Syndrome, Carcinoid Tumor
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors.
- Conditions
- Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor
- Trial name
- NCT04993261
- Testing
- Dual-Energy Computed Tomography
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center